........ 47 Post-HS-110 Follow Up (After HS -110 treatment until disease progression) ................................ ................................ ............ 47 Survival Follow -Up (Progressive Disease until Death) ...................... 47 10.5. Arm 6: On Study Treatment Procedures ................................ ........................ 48 Week 1 Assessments (Day 1) ................................ ............................. 48 Week 2 Assessments ................................ ................................ ........... 48 Week 3 Assessments ................................ ................................ ........... 48 Week 4 Assessments ................................ ................................ ........... 49 Week 5, 6, 8, 9, 11 and 12 Assessments ................................ ............. 49 Week 7 and 13 Assessments ................................ ............................... 49 Week 10 Assessments ................................ ................................ ......... 49 Boosting Visits and Assessments (Week 14 to EOT) ........................ 50 Heat Biologics, Inc. Viagenpumatucel -L Protocol HS110 -102 CONFIDENTIAL Amendment 6, 24 May 2019 Page 15 of 95 10.6. Arm 6: End of Treatment ................................ ................................